A detailed history of China Universal Asset Management Co., Ltd. transactions in Argenx Se stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 5,954 shares of ARGX stock, worth $2.59 Million. This represents 0.3% of its overall portfolio holdings.

Number of Shares
5,954
Previous 5,954 -0.0%
Holding current value
$2.59 Million
Previous $2.34 Million -0.0%
% of portfolio
0.3%
Previous 0.3%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$356.95 - $413.29 $797,783 - $923,703
2,235 Added 60.1%
5,954 $2.34 Million
Q4 2023

May 21, 2024

SELL
$338.91 - $506.01 $757,463 - $1.13 Million
-2,235 Reduced 37.54%
3,719 $1.41 Million
Q4 2023

Jan 23, 2024

BUY
$338.91 - $506.01 $1 Million - $1.5 Million
2,958 Added 388.7%
3,719 $1.42 Million
Q3 2023

May 21, 2024

BUY
$369.35 - $548.43 $136,659 - $202,919
370 Added 94.63%
761 $374,000
Q3 2023

Oct 30, 2023

BUY
$369.35 - $548.43 $136,659 - $202,919
370 Added 94.63%
761 $374,000
Q2 2023

May 21, 2024

SELL
$360.14 - $422.58 $3,601 - $4,225
-10 Reduced 2.49%
391 $152,000
Q2 2023

Jul 27, 2023

SELL
$360.14 - $422.58 $3,601 - $4,225
-10 Reduced 2.49%
391 $152,000
Q1 2023

May 21, 2024

BUY
$334.23 - $403.65 $28,409 - $34,310
85 Added 26.9%
401 $149,000
Q1 2023

Apr 27, 2023

BUY
$334.23 - $403.65 $28,409 - $34,310
85 Added 26.9%
401 $149,000
Q4 2022

May 21, 2024

SELL
$342.17 - $402.31 $1.93 Million - $2.27 Million
-5,638 Reduced 94.69%
316 $119,000
Q4 2022

Jan 31, 2023

BUY
$342.17 - $402.31 $10,607 - $12,471
31 Added 10.88%
316 $120,000
Q3 2022

Oct 21, 2022

BUY
$343.2 - $395.75 $97,812 - $112,788
285 New
285 $101,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $24.1B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.